The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 09 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2013 Planned end date changed from 1 Oct 2012 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 30 Mar 2012 Planned end date changed from 1 Sep 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.